Stafford v. Rite Aid Corporation

District Court, S.D. California·Decided July 30, 2020·No. 3:17-cv-01340·Unknown

Opinion

BRYON STAFFORD, Individually Lead Case No.: 3:17-cv-01340-AJB-JLB and on Behalf of All Others (Consolidated with Case No. 3:18-cv- Similarly Situated, 00152-AJB-JLB) Plaintiff, ORDER: v.

RITE AID CORPORATION, (1) GRANTING PLAINTIFFS’ Defendant. MOTION TO APPOINT INTERIM CO-LEAD CLASS COUNSEL, (Doc. No. 105);

(2) GRANTING EX PARTE MOTION TO STAY PENDING APPEAL, (Doc. No. 183); AND

(3) STAYING PLAINTIFFS STAFFORD AND JOSTEN’S MATTERS Presently pending before the Court are: (1) Bryon Stafford (“Stafford”) and Robert Josten’s (“Josten”) (collectively, “Plaintiffs”) unopposed motion to appoint interim co-lead class counsel. (Doc. No. 105), and (2) Defendant Rite Aid Corporation’s (“Rite Aid”) ex parte motion to stay pending appeal. (Doc. No. 183.) Plaintiff Stafford filed an opposition 1 to Rite Aid’s ex parte motion. (Doc. No. 185.) For the reasons set forth in detail below, the Court GRANTS (1) Plaintiffs’ unopposed motion to appoint, (2) GRANTS Rite Aid’s ex parte motion, and (3) STAYS Plaintiffs’ matters pending Rite Aid’s appeal. This is a putative class action filed against Rite Aid Corporation and Rite Aid Hdqtrs. Corporation (“Rite Aid HQ”) for an alleged deceptive and unfair pricing scheme involving Rite Aid’s Rx Savings Program. (Third Amended Complaint (“TAC”), Doc. No. 145.) As general background, the overwhelming majority of Rite Aid’s clients are enrolled in either a private or public health care plan that covers some or all medical and pharmaceutical expenses. (Id. ¶ 28.) In almost every one of these plans, the cost of prescription drugs is shared between the third-party payor (“TPPs”) (i.e., the health insurance plan) and the actual user of the drug (i.e., the plan participant). (Id.) When a plan participant fills a prescription at a pharmacy under a third-party health care plan, the plan pays a portion of the cost, and the plan participant pays the remaining portion of the cost directly to the pharmacy as a copayment. (Id.) Because of the cost savings associated with generic drugs as opposed to brand name drugs, TPPs incentivize plan participants to purchase generic drugs by offering a lower price, which in turn, results in a lower copayment. (Id. ¶ 6.) By law, Rite Aid cannot charge a copayment that exceeds its “usual and customary” price, which is generally defined within the pharmaceuticals industry. (Id. ¶ 7.) The process by which financial responsibility between TPPs and plan participants is determined is called “adjudication.” Rite Aid contracts with pharmacy benefit managers (“PBMs”) and TPPs to “adjudicate” the claims of customers for prescription drug coverage. (Doc. No. 78-1 at 7.) The contracts specify Rite Aid’s obligations to the TPP or PBM when submitting claims for prescription coverage at the point of sale, as well as the amount Rite Aid will receive as payment when filling prescriptions. (Id. at 8.) Generally, the TPP or PBM determines the amount of reimbursement according to those contracts as well as the copayment or deductible amount. (Id.) The TPP or PBM then transmits the information 2 back to Rite Aid, instructing Rite Aid on the amount to collect from the customer. (Id.) Plaintiffs allege Rite Aid overcharges customers for generic prescription drugs by submitting to TPP/PBMs claims for payment at prices that Rite Aid has inflated above its “usual and customary” prices. (TAC ¶ 8.) As a result, customers who purchase generic prescription drugs through third-party plans pay copayments that are significantly higher than Rite Aid’s “usual and customary” prices for those same drugs. (Id.) Central to this scheme, according to Plaintiffs, is the Rx Savings Program. (Id. ¶ 9.) The Rx Savings Program allows cash-paying customers (customers who pay for prescription drugs without using insurance) to buy the most commonly prescribed generic drugs at significantly discounted prices. (Id.) The Rx Savings Program prices are often significantly lower than the prices Rite Aid reports to health insurance companies as Rite Aid’s “usual and customary” prices. (Id.) Plaintiffs claim Rite Aid was required by law to report to the TPP/PBMs the Rx Savings Program prices as Rite Aid’s “usual and customary” prices for the prescription generic drugs. (Id. ¶ 11.) The failure to do so distorted the overall prescription calculations, resulting in higher copayments to customers. (Id.) Based on this alleged scheme, Plaintiff Stafford brings claims against Rite Aid for: (1) negligent misrepresentation, (2) unjust enrichment, (3) violation of the Consumer Legal Remedies Act (“CLRA”), (4) and violation of the California Unfair Competition Law (“UCL”). Plaintiff Josten brings similar claims, and asserts an additional claim for declaratory and injunctive relief. (Doc. No. 146 at 42.) Plaintiff Stafford’s Complaint was first filed in June 30, 2017. (Doc. No. 1.) A First Amended Complaint was filed on July 28, 2017, (Doc. No. 18), and Rite Aid moved to dismiss for failure to state a claim. (Doc. No. 19.) The Court granted Rite Aid’s motion to dismiss with leave to amend. Plaintiff Stafford filed a Second Amended Complaint on January 9, 2018. (Doc. No. 30.) On January 23, 2018, another plaintiff, Plaintiff Josten, instituted a substantially similar action against Rite Aid. (See Case No. 18-cv-00152-AJB- 3 JLB, Doc. No. 1.) Plaintiff Stafford and Josten’s actions were consolidated by the Court on October 24, 2019. (Doc. No. 101.) On January 23, 2018, Rite Aid filed its second motion to dismiss Plaintiff Stafford’s Second Amended Complaint for failure to state a claim. (Doc. No. 32-1.) On September 28, 2018, the Court denied Rite Aid’s motion to dismiss, holding that Plaintiff Stafford plausibly stated a claim on all four causes of action. (Id.) On June 17, 2019, Ride Aid then filed a motion to compel arbitration. (Doc. No. 78.) On February 25, 2020, the Court denied the motion to compel arbitration, holding Rite Aid failed to show equitable estoppel should apply, thus Rite Aid did not have a right to arbitrate. (Doc. No. 134.) The Court concluded that in any event, Rite Aid waived any rights to compel arbitration by filing multiple motions to dismiss on the merits. (Id.) On March 24, 2020, Rite Aid filed a notice of appeal of the Court’s order denying the motion to compel Stafford to arbitration. (Doc. No. 148.) Rite Aid similarly filed two motions to dismiss in Plaintiff Josten’s case before filing a motion to compel arbitration, which is currently pending before the Court. (Case No. 18- cv-00152-AJB-JLB, Doc. Nos. 15, 28.) On March 3, 2020, before Rite Aid filed the notice of appeal, the parties filed a joint motion for leave to amend both Stafford’s and Josten’s Complaints to add party defendant Rite Aid HQ, which was granted by the Court. (Doc. No. 136.) Rite Aid HQ also filed motions to compel Stafford and Josten to arbitration, which currently pending before the Court, along with Rite Aid’s motion to compel Josten to arbitration. (Doc. Nos. 114, 163, 166.) On June 10, 2020, Rite Aid filed an ex parte motion to stay pending resolution of its appeal to the Ninth Circuit. (Doc. No. 183.) Stafford opposed. (Doc. No. 185.) This order follows. III. PLAINTIFFS’ MOTION TO APPOINT INTERIM CO-LEAD CLASS First, Stafford and Josten seek an order appointing Robbins Geller Rudman & Dowd 4 LLP (“Robbins Geller”) and Scott+Scott Attorneys at Law LLP (“Scott+Scott”) as Interim Co-Lead Class Counsel. (Doc. No. 105.) Rite Aid filed a non-opposition to the motion. (Doc. No. 108.) “The court may designate interim counsel to act on behalf of a putative class before determining whether to certify the action as a class action.” Fed. R. Civ. P. 23(g)(3). Where multiple firms seek appointment as class counsel, “the court must appoint the applicant best able to represent the interests of the class.” Fed. R. Civ. P.

Stafford v. Rite Aid Corporation, (S.D. Cal. 2020).

Stafford v. Rite Aid Corporation (Stafford v. Rite Aid Corporation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Landis v. North American Co.
299 U.S. 248 (Supreme Court, 1936)
Hilton v. Braunskill
481 U.S. 770 (Supreme Court, 1987)
Clinton v. Jones
520 U.S. 681 (Supreme Court, 1997)
Nken v. Holder
556 U.S. 418 (Supreme Court, 2009)
Leiva-Perez v. Holder
640 F.3d 962 (Ninth Circuit, 2011)
O'Brien v. O'Laughlin
557 U.S. 1301 (Supreme Court, 2009)
Lockyer v. Mirant Corp.
398 F.3d 1098 (Ninth Circuit, 2005)
Sanford v. Memberworks, Inc.
483 F.3d 956 (Ninth Circuit, 2007)
In re Kentucky Elkhorn Coal Corp.
19 F.2d 264 (E.D. Kentucky, 1926)
Alascom, Inc. v. ITT North Electric Co.
727 F.2d 1419 (Ninth Circuit, 1984)
Britton v. Co-Op Banking Group
916 F.2d 1405 (Ninth Circuit, 1990)